

# Miles Andrews

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7770611/miles-andrews-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50 papers	4,570 citations	23 h-index	67 g-index
68 ext. papers	6,190 ext. citations	14.7 avg, IF	4.96 L-index

#	Paper	IF	Citations
50	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , <b>2018</b> , 359, 97-103	33.3	1895
49	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , <b>2017</b> , 170, 1120-1133.e17	56.2	659
48	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , <b>2018</b> , 24, 1649-1654	50.5	377
47	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 181-193	21.7	168
46	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1-7	8.7	138
45	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 22699-22709	11.5	119
44	MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 351-60	12.5	96
43	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , <b>2019</b> , 29, 846-861	24.7	91
42	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 1084-9	8.7	90
41	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e378-e389	21.7	88
40	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1558-1563	8.7	72
39	Apocynin but not allopurinol prevents and reverses adrenocorticotrophic hormone-induced hypertension in the rat. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, 910-6	2.3	72
38	The nitric oxide system in glucocorticoid-induced hypertension. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 1035-43	4.3	69
37	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , <b>2021</b> , 27, 1432-1441	50.5	57
36	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , <b>2021</b> , 374, 1632-1640	33.3	52
35	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , <b>2017</b> , 9, 1011-1029	12	49
34	BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e448-51	2.2	47

33	Human perforin mutations and susceptibility to multiple primary cancers. <i>OncolImmunology</i> , <b>2013</b> , 2, e24185	7.2	46
32	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3366-3376	12.9	43
31	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 411	8.4	38
30	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors <b>2019</b> ,		32
29	PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. <i>Molecular Cancer</i> , <b>2017</b> , 16, 112	42.1	27
28	Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 367	5.3	24
27	Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , <b>2017</b> , 58, e109-e112	1.3	21
26	Cancer Evolution during Immunotherapy. <i>Cell</i> , <b>2017</b> , 171, 740-742	56.2	18
25	Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2015</b> , 40, 121-3	2.2	14
24	Systems analysis identifies miR-29b regulation of invasiveness in melanoma. <i>Molecular Cancer</i> , <b>2016</b> , 15, 72	42.1	14
23	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 946	8.4	13
22	Patterns of care for metastatic renal cell carcinoma in Australia. <i>BJU International</i> , <b>2015</b> , 116 Suppl 3, 36-41	5.6	12
21	Evolving role of tumor antigens for future melanoma therapies. <i>Future Oncology</i> , <b>2014</b> , 10, 1457-68	3.6	11
20	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. <i>Nature Communications</i> , <b>2020</b> , 11, 853	17.4	10
19	Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats. <i>Clinical and Experimental Hypertension</i> , <b>2004</b> , 26, 499-509	2.2	9
18	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , <b>2020</b> , 11, 1839	17.4	9
17	The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. <i>OncolImmunology</i> , <b>2014</b> , 3, e946367	7.2	8
16	Adrenocorticotrophic hormone, blood pressure, and serum erythropoietin concentrations in the rat. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 457-61	2.3	8

15	Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in rats. <i>Clinical and Experimental Hypertension</i> , <b>2007</b> , 29, 465-78	2.2	7
14	A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. <i>Melanoma Research</i> , <b>2014</b> , 24, 144-9	3.3	6
13	A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. <i>Cancer Reports</i> , <b>2019</b> , 2, e1183	1.5	5
12	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors <b>2019</b> ,		5
11	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5222-34	12.9	4
10	The good, the (not so) bad and the ugly of immune homeostasis in melanoma. <i>Immunology and Cell Biology</i> , <b>2018</b> , 96, 497-506	5	3
9	MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells <b>2013</b> , 1,		3
8	Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2016</b> , 41, 354-356	2.2	3
7	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi382	10.3	2
6	Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy <b>2015</b> , 3, P126		2
5	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 1107-23	5.1	2
4	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. <i>Oncotarget</i> , <b>2017</b> , 8, 1992880	7.2	2
3	Reply to XComment on XEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyX <i>British Journal of Cancer</i> , <b>2017</b> , 116, e15	8.7	1
2	Interaction between Targeted Therapy and Immunotherapy <b>2018</b> , 268-285		
1	Predictors of Response to Immune Checkpoint Blockade <b>2018</b> , 525-544		